GlassScriptPhysician profile
Ludmil K Manov
NPI 1629098108
$3,619.37
in general payments reported to CMS, 2019-2025
21 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $571 · 2021: $481 · 2022: $642 · 2023: $471 · 2024: $466 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.35 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,633.90 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $476.85 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $324.91 | 2020-2023 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $202.41 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $162.53 | 2022-2024 | Qelbree, Qelbree |
| Abbvie INC. | $112.01 | 2023-2025 | |
| Comsort, INC | $100.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.42 | 2019 | |
| Corium, LLC | $78.08 | 2022-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $66.63 | 2025 | Cobenfy |
| Lundbeck LLC | $66.04 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $56.05 | 2020-2021 | |
| Tris Pharma INC | $53.95 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $42.65 | 2020-2024 | |
| Adlon Therapeutics L.P. | $35.74 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $31.72 | 2019 | |
| Jazz Pharmaceuticals INC. | $30.51 | 2022 | |
| Neuronetics, INC. | $17.35 | 2019 | |
| Merck Sharp & Dohme LLC | $16.14 | 2022 | |
| Alkermes, INC. | $12.24 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ludmil Manov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.